ENZ - Enzo Biochem, Inc.

NYSE - NYSE Delayed Price. Currency in USD

Enzo Biochem, Inc.

527 Madison Avenue
New York, NY 10022
United States

IndustryDiagnostics & Research
Full Time Employees460

Key Executives

NameTitlePayExercisedYear Born
Dr. Elazar RabbaniCo-Founder, Chairman, CEO & Sec.1.29MN/A1943
Mr. Barry W. WeinerFounder, Pres & Director1.09MN/A1950
Ms. Kara CannonCorp. VP of Commercial Operation292.8kN/A1968
Dr. Dieter SchapfelChief Medical Director - Enzo Clinical Labs403.28kN/A1963
Mr. Bruce A. DeyVP of Sales & Marketing - Enzo Clinical Labs348.2kN/A1958
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in Life Sciences Products, Clinical Laboratory Services, and Therapeutics segments. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 34 patient service centers in New York and New Jersey; and a free standing ‘STAT' or rapid response laboratory in New York City and Connecticut, as well as a full-service phlebotomy department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

Corporate Governance

Enzo Biochem, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 9; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.